Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target

BACKGROUND: The methylation inhibitor 5-Aza-2′-deoxycytidine (decitabine, DAC) has a great therapeutic value for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). But decitabine monotherapy was associated with a relatively low rate of complete remission in AML and MDS. We aimed to in...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Kongfei, Hu, Chao, Mei, Chen, Ren, Zhigang, Vera, Juan Carlos, Zhuang, Zhengping, Jin, Jie, Tong, Hongyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082426/
https://www.ncbi.nlm.nih.gov/pubmed/24923330
http://dx.doi.org/10.1186/1479-5876-12-167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082426/
https://www.ncbi.nlm.nih.gov/pubmed/24923330
http://dx.doi.org/10.1186/1479-5876-12-167

Ejemplares similares